The Tylenol autism lawsuit: where MDL 3043 stands after the Daubert exclusion and summary judgment

The Tylenol autism litigation is the most prominent example of a mass tort that's been substantively reshaped by Daubert and summary judgment rulings rather than by trial verdicts or settlement negotiations. The federal multidistrict litigation, MDL 3043 (In re Acetaminophen ASD/ADHD Products Liability Litigation), was centralized before Judge Denise Cote in the U.S. District Court for the Southern District of New York in October 2022. By August 2024, the MDL had been dismissed on summary judgment after Judge Cote excluded all of the plaintiffs' general causation expert witnesses in a December 2023 Daubert ruling. The plaintiffs' appeal to the U.S. Court of Appeals for the Second Circuit had oral argument on November 17, 2025, and a decision is pending.

The case alleges that prenatal exposure to acetaminophen (the active ingredient in Tylenol and most generic pain relievers) causes autism spectrum disorder and attention-deficit/hyperactivity disorder in children. The litigation involves Johnson & Johnson (manufacturer of brand-name Tylenol) along with major retailers (Walmart, CVS, Walgreens, Costco, Rite Aid) and generic manufacturers who sold acetaminophen products without warnings about the alleged neurodevelopmental risks. At the time of dismissal, the federal MDL had approximately 500 individual cases plus a master complaint structure that other plaintiffs could join through Short Form Complaints.

The procedural posture in 2026 is unusual for an active mass tort. The federal litigation is effectively dormant pending the Second Circuit appeal. State court cases continue in various jurisdictions on independent legal frameworks. The FDA took regulatory action in 2026 that arguably supports the plaintiffs' scientific theory, which has been cited in the appellate proceedings. Whether the federal MDL revives depends on the Second Circuit's ruling.

This is the litigation's procedural history, the scientific dispute that produced the Daubert exclusion, the appellate framework that may revive the case, what's happening in state courts independently, and what filings remain procedurally possible.

The scientific basis and the Daubert exclusion

The litigation rests on epidemiological research suggesting an association between prenatal acetaminophen exposure and increased risk of neurodevelopmental disorders in offspring. Multiple studies over the past decade have found this association, including:

A 2021 consensus statement published in Nature Reviews Endocrinology, signed by 91 scientists and clinicians, calling for precautionary action regarding acetaminophen use during pregnancy based on evidence of "moderate to strong" association with neurodevelopmental disorders.

A 2021 meta-analysis in six European population-based cohorts published in the Journal of the European Academy of Paediatric Societies finding statistically significant associations between prenatal acetaminophen exposure and autism spectrum disorder and ADHD symptoms.

A 2023 JAMA Pediatrics study finding that children exposed to acetaminophen during fetal development had approximately 34% higher risk of developing autism compared to unexposed children.

The plaintiffs' theory of causation rests on these epidemiological associations combined with biological mechanisms (oxidative stress, endocrine disruption, immune system effects) that could plausibly explain the observed associations.

The defense position has consistently been that the epidemiological associations are confounded by other factors (genetic predisposition, underlying maternal conditions that prompted acetaminophen use, exposure to other risk factors) and that the studies haven't established causation rather than mere association. Industry-funded analyses have produced findings supporting the safety of acetaminophen during pregnancy.

Judge Cote's December 7, 2023 Daubert ruling found that all five of the plaintiffs' general causation experts had failed to apply reliable scientific methodology. The ruling excluded testimony from Dr. Andrea Baccarelli (a Harvard public health dean whose research has been central to the precautionary movement), Dr. Roberta Ness, and three other experts. The exclusion of general causation experts effectively prevented the plaintiffs from establishing that acetaminophen can cause autism or ADHD, which is a threshold requirement under federal evidence rules.

In August 2024, Judge Cote granted summary judgment for the defendants based on the absence of admissible general causation evidence. The dismissal applied to all federal MDL cases.

The Second Circuit appeal

The plaintiffs appealed Judge Cote's rulings to the U.S. Court of Appeals for the Second Circuit. The appeal challenges both the Daubert exclusion of the expert witnesses and the resulting summary judgment.

Oral argument was held on November 17, 2025. Reporting on the argument indicated that two of the three appellate judges questioned whether Judge Cote was too aggressive in excluding the plaintiffs' expert evidence. Specifically, the appellate panel raised concerns about whether some of the plaintiffs' expert testimony may have been admissible under the Daubert framework, even if some methodological criticisms were valid. The third judge appeared more sympathetic to the trial court's analysis.

The Second Circuit's decision is pending as of May 2026. Several outcomes are possible:

Full affirmance of Judge Cote's rulings. The Daubert exclusion stands, the summary judgment stands, and the federal MDL remains dismissed. Plaintiffs would have limited options for federal court litigation under the current theory.

Reversal on the Daubert ruling. The Second Circuit could find that the trial court was too aggressive in excluding expert testimony and remand for reconsideration of which experts should be allowed to testify. This would revive the litigation but require renewed proceedings.

Partial reversal. The Second Circuit could affirm some aspects of the Daubert ruling while reversing others, allowing some but not all of the excluded experts to testify on remand.

The timing of the Second Circuit decision is uncertain. Most circuit decisions issue within 6-12 months of oral argument, but complex appeals can take longer. A decision by late 2026 or early 2027 is consistent with the typical timeline.

The FDA acetaminophen label initiative

Outside the litigation, federal regulatory action has changed the context. In April 2026, the FDA initiated a labeling update for acetaminophen products that would acknowledge a potential association between prenatal acetaminophen exposure and increased risk of autism and ADHD. The action followed President Trump's announcement that the FDA would notify doctors of the possible link.

The FDA action is significant for several reasons:

It represents the first federal regulatory acknowledgment of the scientific basis for the plaintiffs' core theory. Previously, the FDA had not required acetaminophen labels to address pregnancy-related neurodevelopmental risks.

The plaintiffs filed a new letter with the Second Circuit citing the FDA's actions and noting that the agency's advisory relied on research by Dr. Baccarelli, whose testimony was excluded in the original Daubert ruling. The argument: if a federal regulatory agency relies on the same expert research that the trial court found unreliable, the methodology may be more sound than the trial court concluded.

The FDA action may affect future state court litigation by providing additional regulatory and scientific support for the plaintiffs' theories.

The FDA action arrived after Judge Cote's rulings and the Second Circuit oral argument, so it doesn't directly bear on the legal sufficiency of the rulings under review. But it may inform the broader regulatory and scientific landscape that the appellate court considers.

State court cases continue independently

While the federal MDL is dismissed pending appeal, state court cases on the same underlying theory continue in various jurisdictions. State court litigation isn't bound by federal Daubert rulings; states apply their own evidence standards under variations of the Daubert framework, the older Frye "general acceptance" standard, or other state-specific approaches.

States that have continued to allow Tylenol autism cases to proceed under their own evidentiary standards include various filings in California state court, Pennsylvania (Philadelphia and other counties), and several other jurisdictions. State court cases typically file individually or in coordinated proceedings rather than through MDL-style consolidation.

The state court litigation operates on independent timelines from the federal appeal. Some state court cases have proceeded through preliminary stages, with defendants moving to exclude similar expert evidence under the applicable state standards. The outcomes have varied by jurisdiction.

For plaintiffs whose facts and timing make state court litigation viable, this remains an active option even with the federal MDL dismissed.

The MAUDE database and the scope of potential claims

The FDA's Manufacturer and User Facility Device Experience (MAUDE) database includes adverse event reports related to acetaminophen, with thousands of reports specifically mentioning autism spectrum disorder. As of late 2025, the MAUDE database contained approximately 3,247 reported cases linking prenatal acetaminophen use to neurodevelopmental disorders, with approximately 78% specifically mentioning autism spectrum disorder.

The MAUDE reports aren't evidence of causation; they reflect parents' beliefs and observations rather than scientifically established causation. But they indicate the scale of the population that perceives a connection between acetaminophen exposure and neurodevelopmental conditions, which has implications for the potential scope of future litigation if the legal framework supports it.

Eligibility for filing in the current procedural posture

The question of who can file Tylenol autism lawsuits in 2026 has a complicated answer because of the federal MDL's dismissal.

For federal court filing through MDL 3043: cases cannot currently be filed into the dismissed MDL. If the Second Circuit reverses on the Daubert ruling, federal filings may resume; until then, the federal docket is closed for new cases on this theory.

For state court filing: cases on the underlying theory can be filed in state courts that haven't independently excluded the plaintiffs' expert evidence. The strategic analysis depends on the specific state's evidentiary standards, statute of limitations, and procedural rules. Filing in plaintiff-favorable state jurisdictions (states with more permissive expert evidence rules or longer statutes of limitations) may be viable.

For potential future federal filings: if the Second Circuit reverses, new federal cases may become viable. The procedural framework would likely revive MDL 3043 (or create a successor MDL) for newly filed cases. Plaintiffs whose facts support filing should consider monitoring the Second Circuit decision.

The basic substantive criteria for cases (if the legal framework is restored) would be:

Maternal use of acetaminophen-containing products during pregnancy, particularly during specific developmental windows (the second and third trimesters).

A child subsequently diagnosed with autism spectrum disorder or ADHD by a qualified medical professional.

Documentation supporting both the pregnancy acetaminophen use (medical records, pharmacy records, witness statements) and the child's diagnosis (medical records, diagnostic reports).

The case falls within the applicable statute of limitations under the state where suit is filed.

The strongest cases under the prior framework involved sustained acetaminophen use during pregnancy (rather than occasional use) and clear medical diagnoses of autism or ADHD.

How this differs from other active mass torts

The Tylenol autism procedural posture is unusual. Most active mass torts are either heading toward settlement (like the J&J talc litigation which is in active mediation under court order) or producing substantial verdicts (like the Roundup litigation where Bayer has paid over $11 billion). The Tylenol case is in neither posture; it's in appellate limbo with the underlying merits suspended pending review.

The case is structurally similar to mass torts that have been dismissed on Daubert grounds before reaching trial. Some such cases have been revived on appeal and produced substantial outcomes; others have remained dismissed. We cover the broader framework in our overview of how mass tort settlements work.

For prospective plaintiffs and their counsel, the strategic considerations include:

The Second Circuit decision will substantially affect whether the federal MDL revives. Litigants who file before the decision have to commit resources without knowing whether the federal track will be available.

State court litigation provides an alternative track that doesn't depend on federal Daubert ruling. The viability varies by jurisdiction.

The statute of limitations is generally running. Plaintiffs whose children have been diagnosed cannot wait indefinitely for the procedural picture to clarify before filing.

The FDA developments may strengthen the plaintiffs' position scientifically but don't resolve the legal framework questions.

What to do if you may have a claim

For potential claimants, the procedural complexity makes professional consultation more important than usual.

Consult with mass tort counsel experienced in the Tylenol autism litigation. Several major plaintiffs' firms (Keller Postman, Wisner Baum, Beasley Allen, Motley Rice, and others) have substantial Tylenol autism case inventories and understand the current procedural landscape.

Most consultations are free, and contingency fee arrangements mean no out-of-pocket cost for representation. The contingency percentage (typically 33-40% of any recovery) applies only if the case produces recovery.

Gather documentation of pregnancy acetaminophen use. Pharmacy records, prescription records, medical records noting OTC medication use during prenatal visits, witness statements from family members or partners. Stronger documentation supports stronger cases.

Gather documentation of the child's diagnosis. Formal diagnosis from a qualified medical professional, diagnostic reports, treatment records, educational records relating to the diagnosis.

Calendar the statute of limitations. State limits vary, typically 2 to 4 years from the date the plaintiff knew or should have known of the connection between acetaminophen exposure and the child's condition. The "discovery rule" in many states extends the deadline to when the plaintiff became aware of the alleged connection, but this requires fact-specific analysis.

Consider state court filing options. Even with federal MDL dismissed, state court litigation may be viable depending on the facts and jurisdiction. Counsel can advise on which state filings make sense.

Monitor the Second Circuit decision. The appellate ruling will substantially affect the strategic landscape. Counsel will track the decision and advise on implications for individual cases.

Don't rely on the federal MDL alone. The dismissal means the federal MDL isn't currently accepting new cases. Strategic planning needs to account for both the appellate uncertainty and the available alternative tracks.

The Tylenol autism litigation represents one of the more complex procedural situations in current mass tort litigation. The substantive merits may be strong (the scientific basis has substantial support and is now reflected in FDA regulatory action) but the legal framework has been disrupted by the Daubert exclusion and summary judgment. Whether the litigation revives depends substantially on the Second Circuit's pending decision and on continued state court development.

For families who used acetaminophen during pregnancy and have a child diagnosed with autism or ADHD, the procedural complexity makes professional consultation essential. The path forward isn't as straightforward as it is in mass torts with clearer settlement or trial trajectories. But viable options exist for many cases, particularly when professional counsel can navigate the federal-state distinction and the appellate uncertainty. The litigation isn't over despite the federal dismissal; it's in a particular procedural posture that requires strategic navigation rather than the routine filing approach that works in more mature mass torts.